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Introduction
Historically controlled studies (HCSs) compare data
from two or more separately conducted studies – the
new treatment arm, usually prospectively collected, is
compared to a control arm of retrospective data. HCSs
are frequently undertaken in paediatric oncology (PO),
where there is a widespread belief that RCTs cannot be
performed in rare diseases. This is despite the potential
biases in HCSs being well known – e.g. other factors
change over time.
Aim
To compare the outcome of the control group of RCTs
in PO with that anticipated in the sample size calcula-
tion. The assumption being that, had an HCS been car-
ried out instead, the control arm data in the historical
control study would have likely been that utilized in the
RCT’s sample size calculation.
Methods
A search for published PO RCTs was conducted using
the Cochrane Central database from March 2011 to
database inception. Search terms were “randomi?ed”
plus the disease name in all fields. Only papers reporting
sample size parameters and observed estimates were
included. Data were extracted and compared on antici-
pated and observed outcomes in the control arms (and
experimental arms).
Preliminary results
To date 45 RCTs have been included from 16 tumour
sites: 36 superiority trials, 9 equivalence/non-inferior-
ity; 12 with dichotomous primary endpoints, 33 time-
to-event; mean recruited number of patients was 231
(range: 50 to 2619). In 33 trials the control group did
better than anticipated (in 13 cases >10% absolute dif-
ference), in 11 trials the control group did worse (by
>10% in four); outcome was the same as anticipated in
one trial. The median absolute difference between con-
trol groups’ observed outcome and anticipated out-
come was 5% (range: -21% to +35%); mean difference
was also 5%. In superiority trials, the median difference
was 6%; it was 4% in equivalence/non-inferiority trials.
In trials with a dichotomous endpoint, the median dif-
ference was 7%; it was 5% in trials with a time-to-
event endpoint (8 out of 9 equivalence/non-inferiority
trials had time-to-event endpoint). The median
observed difference between the experimental and con-
trol groups was 0% (range: -16% to 21%); the median
difference between the observed experimental arm out-
come and anticipated control group outcome was 6%
(range: -20% to 45%).
Interpretation
Since the control group (i.e. standard treatment arm) in
RCTs did better than anticipated, non-randomised
HSCs that use similar assumptions for outcome with
standard treatment will overestimate the benefit of new
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